General Information of Drug (ID: DMAHSU0)

Drug Name
Selexipag
Synonyms
Selexipag; NS-304; 475086-01-2; Uptravi; NS 304; ACT-293987; UNII-5EXC0E384L; Selexipag(NS-304); ACT 293987; 5EXC0E384L; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; Selexipag [USAN:INN]; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; Uptravi (TN)
Indication
Disease Entry ICD 11 Status REF
Pulmonary arterial hypertension BB01.0 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 496.6
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Clearance
The oral clearance of drug is 35 L/h []
Elimination
The elimination of drug is 93% via feces and 12% via urine []
Half-life
The concentration or amount of drug in body reduced by one-half in 0.8 - 2.5 hours [2]
Metabolism
The drug is metabolized via the hydrolysis of the acylsulfonamide by the enzyme hepatic carboxylesterase 1 []
Chemical Identifiers
Formula
C26H32N4O4S
IUPAC Name
2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide
Canonical SMILES
CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
InChIKey
QXWZQTURMXZVHJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
9913767
ChEBI ID
CHEBI:90844
CAS Number
475086-01-2
DrugBank ID
DB11362
TTD ID
D0N2SR
INTEDE ID
DR1471
ACDINA ID
D00619
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostacyclin receptor (PTGIR) TTOFYT1 PI2R_HUMAN Agonist [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C8 (CYP2C8)
Main DME
DES5XRU CP2C8_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pulmonary arterial hypertension
ICD Disease Classification BB01.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostacyclin receptor (PTGIR) DTT PTGIR 7.12E-02 -0.13 -0.33
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.93E-03 -2.19E-01 -4.49E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Selexipag (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Selexipag caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [5]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Selexipag due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [6]
Ag-221 DMS0ZBI Moderate Decreased clearance of Selexipag due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [6]
Erdafitinib DMI782S Moderate Decreased clearance of Selexipag due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [7]
Tucatinib DMBESUA Moderate Decreased clearance of Selexipag due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [8]
PF-04449913 DMSB068 Moderate Decreased clearance of Selexipag due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [5]
MK-8228 DMOB58Q Moderate Decreased metabolism of Selexipag caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [9]
Ripretinib DM958QB Moderate Decreased metabolism of Selexipag caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [10]
Fostemsavir DM50ILT Moderate Decreased clearance of Selexipag due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [11]
Bempedoic acid DM1CI9R Moderate Decreased clearance of Selexipag due to the transporter inhibition by Bempedoic acid. Hyper-lipoproteinaemia [5C80] [12]
PF-06463922 DMKM7EW Moderate Increased metabolism of Selexipag caused by PF-06463922 mediated induction of UGT. Lung cancer [2C25] [6]
Capmatinib DMYCXKL Moderate Decreased clearance of Selexipag due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [13]
Selpercatinib DMZR15V Moderate Decreased metabolism of Selexipag caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [6]
IPI-145 DMWA24P Moderate Decreased metabolism of Selexipag caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [14]
Lasmiditan DMXLVDT Moderate Decreased clearance of Selexipag due to the transporter inhibition by Lasmiditan. Migraine [8A80] [15]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Selexipag and Ozanimod. Multiple sclerosis [8A40] [16]
Rucaparib DM9PVX8 Moderate Decreased clearance of Selexipag due to the transporter inhibition by Rucaparib. Ovarian cancer [2C73] [17]
Abametapir DM2RX0I Moderate Decreased metabolism of Selexipag caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [18]
Lefamulin DME6G97 Moderate Decreased metabolism of Selexipag caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [19]
Darolutamide DMV7YFT Moderate Decreased clearance of Selexipag due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [20]
Tedizolid DMG2SKR Moderate Decreased clearance of Selexipag due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [5]
Larotrectinib DM26CQR Moderate Decreased metabolism of Selexipag caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [6]
Pitolisant DM8RFNJ Moderate Increased metabolism of Selexipag caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [5]
Fostamatinib DM6AUHV Moderate Decreased clearance of Selexipag due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [21]
⏷ Show the Full List of 24 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Selexipag 1.6 mg tablet 1.6 mg Oral Tablet Oral
Selexipag 0.6 mg tablet 0.6 mg Oral Tablet Oral
Selexipag 0.8 mg tablet 0.8 mg Oral Tablet Oral
Selexipag 1 mg tablet 1 mg Oral Tablet Oral
Selexipag 1.2 mg tablet 1.2 mg Oral Tablet Oral
Selexipag 0.2 mg tablet 0.2 mg Oral Tablet Oral
Selexipag 0.4 mg tablet 0.4 mg Oral Tablet Oral
Selexipag 1.4 mg tablet 1.4 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7552).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80.
4 FDA Label of Uptravi. The 2020 official website of the U.S. Food and Drug Administration.
5 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6 Cerner Multum, Inc. "Australian Product Information.".
7 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
8 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
9 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
10 Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
11 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
12 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
13 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
14 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
15 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
16 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
17 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
18 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
19 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
20 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
21 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.